In vivo rhIL-7-hyFc treated UCART19 displayed significantly greater cytotoxicity than input UCART19 against CD19+ Ramos and Nalm6 tumor cell lines (Fig. 7i, j), with input controls requiring 2–4-fold greater numbers of effector cells to achieve equivalent cytotoxicity to UCART19 from rhIL-7-hyFc treated mice. The gene discussed is CD19; the disease is neoplasm.